CSPC Pharmaceutical Group (HK:1093) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
CSPC Pharmaceutical Group has entered into an exclusive license agreement with BeiGene for the global development, manufacture, and commercialization of its innovative cancer drug, SYH2039. The deal includes upfront payments of $150 million, with potential milestone payments of up to $1.685 billion, plus royalties. SYH2039, a promising drug targeting MTAP-deficient tumors, has shown strong preclinical results and is currently in Phase I clinical trials in China.
For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.
